References
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021 Dec 31; 59(1):2102730. doi: 10.1183/13993003.02730-2021. PMID: 34667060; PMCID: PMC8719459.
- Dennis RJ, Caraballo L, Garcia E, et al. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17. doi: 10.1186/1471-2466-12-17
- Gonzalez-Garcia M, Caballero A, Jaramillo C, et al. Prevalence, risk factors and underdiagnosis of asthma and wheezing in adults 40 years and older: A population-based study. J Asthma. 2015;52(8):823–830. doi: 10.3109/02770903.2015.1010733
- Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi: 10.1056/NEJMoa1804093
- Xiong XF, Zhu M, Wu HX, et al. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20(1):108. doi: 10.1186/s12931-019-1065-3
- Peters MC, Mekonnen ZK, Yuan S, et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388–394. doi: 10.1016/j.jaci.2013.07.036
- Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32(3):545–554. doi: 10.1183/09031936.00155307
- Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Sala especializada de moléculas nuevas, nuevas indicaciones y medicamentos biológicos. https://www.invima.gov.co/documents/20143/1675737/Acta-No-24-de-2020-SEMNNIMB.pdf2020.
- Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Consulta datos de productos. 2021.
- Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–638. doi: 10.1111/j.1365-2222.2004.1916.x
- Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–261. doi: 10.1183/09031936.01.00092101
- Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi: 10.1056/NEJMoa1403290
- Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi: 10.1016/S0140-6736(12)60988-X
- Izumo T, Tone M, Kuse N, et al. Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study. Ann Transl Med. 2020;8(7):438. doi: 10.21037/atm.2020.04.01
- Perez de Llano LA, Cosio BG, Domingo C, et al. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019;7(7):2277–83 e2. doi: 10.1016/j.jaip.2019.01.017
- De Ferrari L, Chiappori A, Bagnasco D, et al. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? Expert Rev Respir Med. 2016;10(1):29–38. doi: 10.1586/17476348.2016.1111763
- Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune responses. Immunology. 2011;134(4):378–385. doi: 10.1111/j.1365-2567.2011.03499.x
- Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–282. doi: 10.1038/nri3831
- Busse WW, Maspero JF, Rabe KF, et al. Liberty asthma QUEST: phase 3 randomized, Double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35(5):737–748. doi: 10.1007/s12325-018-0702-4
- Bourdin A, Papi AA, Corren J, et al. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021;76(1):269–280. doi: 10.1111/all.14611
- Bagnasco D, Heffler E, Testino E, et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019;15(2):113–120. doi: 10.1080/17425255.2019.1568409
- Flórez-Tanus A, Parra D, Zakzuk J, et al. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018 12;11(1):26. doi: 10.1186/s40413-018-0205-4
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi: 10.1056/NEJMoa1804092
- National Institute for Health and Care Excellence. NICE recommends benralizumab for severe eosinophilic asthma. PharmacoEcon Outcomes News. 2019;819:37. doi: 10.1007/s40274-019-5576-4
- Bateman ED, Khan AH, Xu Y, et al. WITHDRAWN: pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Respir med. 2020;100018. doi: 10.1016/j.yrmex.2020.100018
- Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en salud. Bogotá.D.C: IETS; 2014. https://www.iets.org.co/Archivos/64/Manual_evaluacion_economica.pdf
- Zarate V, Kind P, Chuang LH. Hispanic valuation of the EQ-5D health states: a social value set for Latin Americans. Value Health. 2008 Dec;11(7):1170–1177. Epub 2008 May 16. PMID: 18489516. doi: 10.1111/j.1524-4733.2008.00349.x
- Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715. doi: 10.1016/j.jval.2012.02.008
- de la República B. Tasa Representativa del Mercado (TRM -Peso por dólar) . 2021 [30-Nov-2021]. Available from: https://www.banrep.gov.co/es/estadisticas/trm.
- Consejo Directivo del Instituto de Seguros Sociales. Acuerdo No. 256 DE 2.001 - Manual de Tarifas de la Entidad Promotora de Salud del Seguro Social (ISS). 2001. p. 208. https://www.sanidadfuerzasmilitares.mil.co/transparencia-acceso-informacion-publica/2-normatividad/2-2-busqueda-normas/2-2-2-sistema-busquedas-normas-propio-1/normograma-digsa/subdireccion-salud-digsa/grupo-prestacion-operacion-servicios/normas-externas-aplicadas-al-regimen/acuerdo-256-2001-se-aprueba-manual-tarifas
- O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult asthma Registry. Thorax. 2015;70(4):376–378. doi: 10.1136/thoraxjnl-2013-204114
- DC B, editor. Instituto de Evaluación Tecnológica en Salud. Manual de Procesos Participativos. IETS; 2014. https://www.iets.org.co/Archivos/65/Manual%20Participacion.pdf
- Espinosa O, Rodríguez-Lesmes P, Orozco L, et al. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2022 4;37(3):359–368. doi: 10.1093/heapol/czab146
- Tice JA, Campbell JD, Synnott PG, et al. The effectiveness and value of biologic therapies for the treatment of uncontrolled asthma. J Manag Care Spec Pharm. 2019;25(5):510–514. doi: 10.18553/jmcp.2019.25.5.510
- Buendía JA, Patiño DG. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2022;22(4):575–580. doi: 10.1080/14737167.2022.2011217
- Buendía JA, Patiño DG, Cossio-Giraldo YE. Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. J Asthma. 2021;12:1–8.
- Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. https://ginasthma.org/gina-reports/
- National Asthma Education and Prevention Program. National heart, lung and blood Institute. 2020 focused updates to the asthma management guidelines. 2020. https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates.
- Pedone M, Fanelli F, Serra R, et al. PRS32 cost-effectiveness analysis of dupilumab for the treatment of type 2 severe asthma in Italy. Value Health. 2020;23:23. doi: 10.1016/j.jval.2020.08.1912
- Anderson WC 3rd, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372. doi: 10.1016/j.anai.2019.01.018